Hesham Allam, MD

Neurologist
Neurology
Accepting new patients
Call for an appointment
or

    About me

    Gender

    Male

    Additional languages spoken

    Arabic

    Education & training

    Positions
    Associate Professor
    Board Certifications
    Neurology
    Medical School
    Ain Shams University School of Medicine, Cairo, Egypt
    Residency
    Saint Louis University Hospital, Saint Louis, Missouri - Neurology and Psychiatry
    Fellowship
    Rush University Medical Center, Chicago, Illinois - Neurocritical care

    Specialties

    Clinical locations

    Locations

    SIU Neurology Clinic

    751 N. Rutledge St. Springfield, IL 62702 Suite 3100
    Mon - Fri: 8:00 am-4:30 pm
    Locations

    SIU Pulmonology in Decatur

    102 W. Kenwood Ave. Decatur, IL 62526 Lower Level
    Mon - Fri: 8:00 am-4:30 pm

    Hospital privileges

    • Decatur Memorial Hospital, Decatur, IL
    • HSHS St. John's Hospital, Springfield, IL
    • Memorial Health, Springfield IL

    Clinical trials

    Trial
    Neuroscience Institute

    Sleep for Stroke Management and Recovery Trial

    Active recruiting

    The primary goals of this study are to determine whether treatment of obstructive sleep apnea with positive airway pressure starting shortly after accute ischemic stroke or high risk TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event and (2) improves stroke outcomes at 3 months in patients who experienced ischemic stroke.

    Trial
    Neuroscience Institute

    18-513: A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor XA Inhibitor

    Active not recruiting

    18-513:  The purpose of this study is to evaluate the effect of andexanet alfa (andexanet) versus usual care on the rate of effective homostasis.

    Trial
    Neurology

    Portola: A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor XA Inhibitor

    Active not recruiting

    ANNEXa-1 (18-513): This is a randomized, multicenter clinical trial designed to determine the efficacy and safety of andexanet compared to usual care in patients presenting with acute intracerebral hemorrhage within 6 hours of symptom onset (from the baseline scan) and within 15 hours of taking an oral FXa inhibitor (from randomization). The study will use a prospective, randomized, open-label design, as it is unfeasible to blind the Investigator to the treatment assignment given the many potential therapeutic options available under usual care treatment.

    Trial
    Neurology

    Sleep for Stroke Management and Recovery Trial

    Active recruiting

    The primary goals of this study are to determine whether (1) treatment of obstructive sleep apnea (OSA) with positive airway pressure after acute ischemic stroke or high risk TIA reduces recurrent stroke, acute coronary syndrome (ACS), and all-cause mortality 6 months after the event, and (2) treatment of OSA shortly after acute ischemic stroke improves stroke outcomes at 3 months.